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ABSTRACT
Background. Abnormalities in serum phosphorus, calcium
and parathyroid hormone (PTH) have been associated with
poor survival in haemodialysis patients. This COSMOS (Cur-
rent management Of Secondary hyperparathyroidism: a Multi-
centre Observational Study) analysis assesses the association of
high and low serum phosphorus, calcium and PTH with a rela-
tive risk of mortality. Furthermore, the impact of changes in
these parameters on the relative risk of mortality throughout
the 3-year follow-up has been investigated.
Methods. COSMOS is a 3-year, multicentre, open-cohort, pro-
spective study carried out in 6797 adult chronic haemodialysis
patients randomly selected from 20 European countries.
Results.Using Cox proportional hazard regression models and
penalized splines analysis, it was found that both high and low
serum phosphorus, calcium and PTH were associated with a
higher risk of mortality. The serum values associated with the
minimum relative risk of mortality were 4.4 mg/dL for serum
phosphorus, 8.8 mg/dL for serum calcium and 398 pg/mL for
serum PTH. The lowest mortality risk ranges obtained using as
base the previous values were 3.6–5.2 mg/dL for serum
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phosphorus, 7.9–9.5 mg/dL for serum calcium and 168–674
pg/mL for serum PTH. Decreases in serum phosphorus and
calcium and increases in serum PTH in patients with baseline
values of >5.2 mg/dL (phosphorus), >9.5 mg/dL (calcium) and
<168 pg/mL (PTH), respectively, were associated with im-
proved survival.
Conclusions. COSMOS provides evidence of the association of
serum phosphorus, calcium and PTH and mortality, and sug-
gests survival beneﬁts of controlling chronic kidney disease-
mineral and bone disorder biochemical parameters in
CKD5D patients.
Keywords: calcium, chronic kidney disease, CKD-MBD, cos-
mos, hemodialysis, phosphorous, PTH, survival
INTRODUCTION
Chronic kidney disease-mineral and bone disorder
(CKD-MBD) is a common complication of CKD5D [1],
which has been associated with a higher risk of mortality [2,
3]. In 2003, the Kidney Disease Outcomes Quality Initiative
(K/DOQI) clinical practice guideline recommended for
CKD5D to maintain serum phosphorus between 3.5 and 5.5
mg/dL (1.13–1.78 mmol/L), albumin-corrected serum calcium
between 8.4 and 9.5 mg/dL (2.10–2.37 mmol/L) and serum
parathyroid hormone (PTH) between 150 and 300 pg/mL
(16.5–33.0 pmol/L) [4]. Six years later, the Kidney Disease: Im-
proving Global Outcomes (KDIGO) clinical practice guideline
suggested to maintain serum phosphorus and calcium within
the normal range and serum PTH in the range of two to nine
times the upper normal limit of the assay. However, the level
of evidence for the K/DOQI and KDIGO recommendations
was relatively low [5].
All studies assessing the association between the risk of mor-
tality and abnormalities of CKD-MBD serum parameters have
been observational in nature and therefore they do not prove
causality. Unfortunately, due to the high cost and the current
clinical-epidemiological and experimental evidence, it is un-
likely that large clinical trials addressing this issue will be per-
formed in the future. Thus, according to Hill’s criteria for
causation [6], consistency among different observational stud-
ies performed at different places, circumstances and times is
one of the minimal conditions required to provide adequate
evidence of a causal effect between incidence factors and
consequences.
Previous studies looking for the association between serum
biochemical parameters of CKD-MBD and mortality risk have
been carried out in the USA [3, 7, 8], Latin America [9], some
European countries [10–13] and worldwide including USA,
Asia and European countries [14]. However, no prospective
studies representative of the European haemodialysis popula-
tion have been carried out up to COSMOS [15, 16].
This COSMOS paper analyse the association between serum
phosphorus, calcium, PTH and mortality risk with the aim to
describe the lowest mortality serum values and the safest ranges
for each of these three parameters. Furthermore, in patients
outside the described ranges, the outcome impact of variations
in these CKD-MBD biochemical parameters was assessed.
MATERIALS AND METHODS
COSMOS is a 3-year, multicentre, open-cohort, prospective
observational study surveying bone and mineral disturbances
in 227 dialysis centres from 20 European countries including
patients undergoing maintenance haemodialysis older than
18 years. A total number of 4500 patients were randomly re-
cruited for COSMOS. The number of patients recruited per
country was proportional to the haemodialysis population of
each country. The larger countries were divided into different
geographic areas, and haemodialysis sites were randomly se-
lected within the predeﬁned areas. Within each site 20 patients
were randomly selected. During the 3-year follow-up period,
2297 patients were additionally recruited to replace those pa-
tients leaving the study for any reason, making a total number
of 6797 patients. These replacement patients were not randomly
selected but they should have been on haemodialysis for <1
year. Facilities were identiﬁed using a stratiﬁed, random selec-
tion methodology, the detailed study protocol design has been
previously published [15, 16]. Recruitment of sites and patients
began in February 2005 and ﬁnished in July 2007 and data col-
lection ended in July 2010.
At baseline and every 6 months, clinical, biochemical and
therapeutic relevant information was collected [15, 16]. Intact
PTH levels from sites measuring bio-intact assay were corrected
as it has been already described in detail [16]. Serum PTH va-
lues higher than 3000 pg/mL were removed from the present
analysis (0.4% of observations).
Patients were followed for survival until they died or were
censored because they underwent renal transplantation, left
the study (i.e. referred to other haemodialysis unit or lost by
other reasons) or reached the end of the study, whichever hap-
pened ﬁrst, and they were replaced by new incident patients.
The design of this open-cohort guaranteed the same number
of patients over the 3-year follow-up by replacing lost baseline
randomly selected patients by new incident patients. The out-
come was all-cause mortality and the exposure serum levels of
phosphorus, calcium and PTH. Differences in the characteris-
tics of patients according to serum phosphorus, calcium and
PTH were assessed by using quartiles and one-way analysis of
the variance for continuous variables and chi-squared test for
categorical variables.
Cox proportional hazard regression analysis with time-
dependent variables was used to assess the association between
all-cause mortality and serum phosphorus, calcium and PTH.
The exposure variables were introduced in the Cox models as
continuous variables and ﬁtted by using penalized splines
smoothing. The optimal degree of smoothness was selected
using the Akaike Information Criterion.
Three different multivariate models were used for adjust-
ment containing a total number of 22 variables in the full
model. Model 1 included demographic characteristics and co-
morbidities: age, sex, body mass index (BMI), smoking habit,























diabetes, cardiovascular disease history and parathyroidectomy.
Model 2 included the variables of Model 1 plus the treatment
variables: dialysis type, calcium concentration in the dialysate,
hours of haemodialysis per week, treatment with erythropoietin
stimulating agents (ESAs) and prescription of vitamin D meta-
bolites/analogues (calcitriol, alfacalcidol or paricalcitol), native
vitamin D or calcidol, phosphate binding agents (PBAs)
(calcium-containing PBAs, sevelamer, aluminium-containing
PBAs, lanthanum carbonate or other PBAs) and calcimimetics.
Model 3 (full model) included all previous variables plus ﬁve
biochemical parameters haemoglobin, albumin, phosphorus,
calcium and PTH. All multivariate models were stratiﬁed by
centre. All variables included in Models 2 and 3 as well as
BMI and parathyroidectomy in Model 1 were used as time-
varying covariates.
The serum values of phosphorus, calcium and PTHwith the
minimum log (hazard ratio, HR) were used as reference (HR =
1.0) (Figure 1). The lowest mortality risk ranges or ‘safest
ranges’ were estimated as those serum ranges with a hazard
ratio ≤1.1 (≤10% increase in the relative risk of mortality).
Afterwards, serum values of all patients were categorized as
below, within and above the lowest mortality risk ranges, and
the association of these categories with mortality was assessed.
Serum categories were used as time-varying variables, and the
reference (HR = 1.0) was the serum values within the estimated
ranges. The multivariate models used for adjustments were the
same as described earlier.
During the 3-year follow-up, every 6 months, taking as ref-
erence the baseline serum values, the association between
changes in serum phosphorus, calcium and PTH and relative
risk of mortality was speciﬁcally assessed in the three groups
of patients in whom previous studies have shown a higher
risk of mortality. The mean serum value of each 6-month
period minus the baseline values was calculated and used as a
time-varying variable. Thus, negative and positive values meant
decrease and increase from baseline values, respectively. Crude
and adjusted relative mortality risk was calculated by using pe-
nalized splines smoothing, using the same three multivariate
models described earlier. All statistical analyses were done
using R Statistical Software version 3.0.1 with the ‘survival’
F IGURE 1 : Relative risk of mortality with serum phosphorus, calcium and PTH. Grey boxes show the serum values with the minimum risk of
mortality. Multivariate Model 1 (general and demographic characteristics) included the following variables: sex, age, BMI, aetiology of CKD, time
on haemodialysis, diabetes, cardiovascular disease, parathyroidectomy and smoking habit; Model 2 (treatments): variables from Model 1 plus
prescription of vitamin D receptor activators (calcitriol, alfacalcidol or paricalcitol), native vitamin D, PBAs, calcimimetics, ESAs, type of dialysis
(low ﬂux, high ﬂux, other), hours of haemodialysis per week and dialysate calcium concentration; Model 3 (laboratory parameters): variables from























package (R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
After excluding patients who had only baseline data (no follow-
up), the ﬁnal analysis was carried out in 6307 patients (4318
randomly selected and 1989 replacements) from the following
countries (number of patients and percentages): Germany
(1288, 20.4%), France (858, 13.6%), Italy (727, 11.5%), Spain
(660,10.5%), Poland (462, 7.3%), Portugal (313, 5.0%), Greece
(252, 4.0%), Czech Republic (219, 3.5%), the Netherlands (205,
3.3%), Hungary (187, 3.0%), Romania (180, 2.9%), Austria
(167, 2.6%), UK (135, 2.1%), Sweden (133, 2.1%), Belgium
(132, 2.1%), Denmark (102, 1.6%), Croatia (97, 1.5%), Finland
(69, 1.1%), Switzerland (62, 1.0%) and Slovenia (59, 0.9%). The
main characteristics of patients are shown in Table 1.
After 3-year follow-up, 1642 patients had died (26.0%), 642
were transplanted (10.2%), 239 referred to other haemodialysis
units (3.8%) and 75 were lost to follow-up for other reasons
(1.2%). The mean time of follow-up was 23.5 months (median
24.0 months). Overall, the crude all-cause mortality rate was
13.3 deaths per 100 patient years.
Association between serum markers of bone metabolism
and risk of mortality
Supplementary Tables S1–S3 show patient baseline charac-
teristics by quartiles of serum phosphorus, calcium and PTH as
potential confounders. Most demographic characteristics,
comorbidities and laboratory parameters varied among the dif-
ferent quartiles of serum phosphorus, calcium and PTH.
After adjustment with the three multivariate models, both
high and low levels of serum phosphorus, calcium and PTH
were associated with a higher risk of mortality (Figure 1), but
the 95% conﬁdence interval (95% CI) for low serum calcium
and high serum PTH was wider.
The minimum relative risk of mortality (HR = 1.0) was
found at 4.4 mg/dL for serum phosphorus, 8.8 mg/dL for
serum calcium and 398 pg/mL for serum PTH (Figure 1).
The lowest mortality risk ranges or safest ranges (HR ≤ 1.1 in
Figure 1) were 3.6 (95% CI: 3.1–4.1) to 5.2 (95% CI: 4.9–5.5)
mg/dL for serum phosphorus, 7.9 (95% CI: 5.8–8.4) to 9.5
(95% CI: 9.3–9.7) mg/dL for serum calcium and 168 (95% CI:
85–238) to 674 (95% CI: 450–not estimable) pg/mL for serum
PTH. Serum values below and above these ranges were asso-
ciated with a higher relative risk of mortality (Table 2), except
for serum calcium below the range which did not reach statis-
tical signiﬁcance. At baseline, the highest percentages of pa-
tients outside the safest risk ranges were found in serum
phosphorus and calcium above ranges (50.9 and 25.7% respect-
ively, Table 3) and PTH below the range (40.7%, Table 3). These
three groups also represent the three situations more frequently
associated with a higher risk of mortality. Only 14.9% of
patients were within the safest mortality risk ranges considering
all three serum values simultaneously.
Association between changes in serum phosphorus,
calcium and PTH and risk of mortality
In patients with baseline serum phosphorus or calcium
values within the lowest mortality ranges [3.6–5.2 mg/dL for
serum phosphorus (Figure 2A), 7.9–9.5 mg/dL for serum
calcium (Figure 3A)], the phosphorus or calcium increases or
decreases from baseline values were associated with a higher
risk of mortality.
In patients with baseline serum phosphorus and calcium
values above the lowest mortality risk ranges, i.e. >5.2 mg/dL
for serum phosphorus (Figure 2B) and >9.5 mg/dL for serum
calcium (Figure 3B), the reduction in serum phosphorus or
calcium towards the safest range was associated with a lower
relative risk of mortality. However, a decrease in serum phos-
phorus or calcium beyond the safest range was associated
with increment in the relative risk of mortality (Figures 2B
and 3B).
In patients with baseline serum PTH within the lowest and
safest mortality range (168–764 pg/mL), increases or decreases
in serum PTH did not show signiﬁcant association with the risk
of mortality (Figure 4A). In contrast, in patients with baseline
serum PTH below the COSMOS safest ranges (<168 pg/mL),
increases in serum PTH were associated with lower mortality
risk (Figure 4B).
DISCUSSION
In COSMOS, the ﬁrst 3-year prospective study surveying
CKD-MBD parameters in CKD5D patients, which due to its
design fully represents the haemodialysis European
Table 1. Main baseline characteristics of patients
Sex (n, % males) 6307 60.7
Age (years) (n, mean ± SD) 6307 64.0 ± 14.4
BMI (kg/m2) (n, mean ± SD) 6302 25.3 ± 5.1
Current smokers (n, %) 6299 13.9
Diabetics (n, %) 6306 30.7
CVD history (n, %) 6300 72.1
Parathyroidectomy (n, %) 6307 4.9
Months on HD (n, mean ± SD) 6307 38.9 ± 49.5
Hours of dialysis per week (n, mean ± SD) 6307 12.0 ± 2.1
Dialysis technique (n) 6307
HD conventional low ﬂux (%) 54.1
HD conventional high ﬂux (%) 37.1
Haemodiaﬁltration and other (%) 8.8
Calcium conc. in dialysate (n) 6088
2.5 mEq/L (%) 30.0
3.0 mEq/L (%) 50.0
3.5 mEq/L (%) 19.9
Treated with PBAs (n, %) 6297 85.0
Treated with VDRAs (n, %) 6305 47.5
Treated with calcimimetics (n, %) 6270 6.2
Treated with ESAs (n, %) 6300 90.4
Phosphorus (mg/dL) (n, mean ± SD) 6291 5.4 ± 1.4
Calcium (mg/dL) (n, mean ± SD) 6087 9.1 ± 0.7
PTH (pg/mL) (n, median [IQR]) 6221 210.8 [269.0]
Albumin (g/dL) (n, mean ± SD) 6164 3.8 ± 0.5
Haemoglobin (g/dL) (n, mean ± SD) 6258 11.4 ± 1.4
n, number of patients; BMI, body mass index; HD, haemodialysis; CVD, cardiovascular
disease; PBAs, phosphate binding agents; VDRAs, Vitamin D receptor activators; ESAs,























population [16], a signiﬁcant association between high and
low serum phosphorus, calcium and PTH levels andmortality
was observed. In addition, we identiﬁed the serum values of
the three biochemical parameters in which the minimum
mortality risk was observed and also the ranges in which
the lowest relative risk of mortality was observed (for serum
phosphorus: 4.4 mg/dL, range 3.6–5.2 mg/dL, for serum cal-
cium 8.8 mg/dL, range: 7.9–9.5 mg/dL, for PTH 398 pg/mL,
range 168–764 pg/mL). The serum value ranges found in
COSMOS are proposed as a complement or alternative to
the existing KDOQI and KDIGO ranges, provided they can
be conﬁrmed in other non-European populations. Further-
more, the mortality risk impact of changes in these three
serum CKD-MBD parameters during the 3-year follow-up
was analysed showing that decreases in serum phosphorus
and calcium and increases in serum PTH towards safest
ranges were associated with a lower relative risk of mortality.
These new COSMOS results provide important and novel in-
formation related to possible beneﬁts on outcomes achieved
through a better control of the main CKD-MBD parameters
in CKD5D patients.
The association between CKD-MBD biochemical para-
meters and mortality has been the subject of numerous obser-
vational studies and reviews [2, 3, 7, 8, 10, 13, 14, 17–33]. The
bulk of evidence including the present results from COSMOS
[9, 11–14, 34–39] has shown that both high and low levels of
serum phosphorus, calcium and PTH are associated with an in-
creased risk of mortality. In most of these studies, the assess-
ment of the association of the CKD-MBD serum parameters
and mortality has been carried out by categorization of the ex-
posure variable using arbitrary cut-off values, mostly guideline-
based, and establishing one of them as the reference in the Cox
regression models [2, 3, 7, 8, 10, 14, 26, 27, 29, 33]. In some
studies, the exposure variable was introduced in the Coxmodels
as numeric covariate assuming a linear effect on the outcome
[23, 24, 32, 33, 40]. Categorization of a continuous variable
causes loss of information, and the relationship between the
hazard ratio and serum biochemical parameters of bonemetab-
olism has been found to be non-linear, currently describing a
U-shaped curve.
For the previous reason, the most recent studies have
used regression models that allow modelling non-linear rela-
tionships between continuous variables and relative risk of
mortality, i.e. fractional polynomials [12, 13] and the multi-
variate spline regression models [35, 39]; in the present
study, penalized splines smoothing analyses were used. For
large sample sizes, multivariate fractional polynomials, re-
stricted cubic splines and penalized splines often provide simi-
lar smoothing results [41]. However, the penalized splines
smoothing analyses used in this analysis of COSMOS are
able to detect and correctly model non-linear effects [42], pro-
viding the most consistent ﬁt for the Cox regression models
[43] with a great ﬂexibility [44].
Fouque et al. [12] used fractional polynomials and found a
10% increase in the relative risk of mortality for serum phos-
phorus <2.2 and >6.1 mg/dL, calcium <6.4 and >9.7 mg/dL
and PTH <100 and >1090 pg/mL. In the present study, more
than 10% increase in the relative risk of mortality was found
when serum phosphorus was <3.6 and >5.2 mg/dL, calcium
<7.9 and >9.5 mg/dL and PTH <168 and 674 pg/mL. The dif-
ferences among the optimal ranges in the CKD-MBD serum
parameters found in the study of Fouque and COSMOS
could be mainly explained by the different methodology used.
The identiﬁcation of risk using categorization of serum
values, which has been mostly used in the past, is more difﬁcult
to interpret and compare due to the heterogeneity of the differ-
ent cut-off reference values used in each study [33]. Tentori
et al. [14] used narrower ranges for serum phosphorus and
calcium (0.5 mg/dL increments) and PTH (50 pg/mL
Table 3. Number and percentage of patients within each serum biochemical
parameter category at baseline
Serum phosphorus (mg/dL) <3.6 3.6–5.2 >5.2
Number of patients (%) 523 (8.3) 2569 (40.8) 3199 (50.9)
Serum calcium (mg/dL) <7.9 7.9–9.5 >9.5
Number of patients (%) 326 (5.4) 4199 (69.0) 1562 (25.7)
Serum PTH (pg/mL) <168 168–674 >674
Number of patients (%) 2529 (40.7) 3079 (49.5) 613 (9.9)
Intermediate category was the serum range of each parameter with the lowest mortality risk
(HR≤ 1.1 in Figure 1, ≤10% increase in the relative risk of mortality).
Table 2. Relative risk of mortality [HR (95% CI)] and serum values below, within and above the lowest mortality ranges of serum biochemical parameters
Serum phosphorus (mg/dL) <3.6 3.6–5.2 >5.2
Univariate (n = 6291) 1.87 (1.63–2.14) 1.0 0.96 (0.86–1.07)
Model 1 (n = 6278) 1.80 (1.55–2.09) 1.0 1.21 (1.08–1.37)
Model 2 (n = 6015) 1.59 (1.36–1.86) 1.0 1.28 (1.14–1.45)
Model 3 (n = 5590) 1.34 (1.13–1.59) 1.0 1.34 (1.18–1.53)
Serum calcium (mg/dL) <7.9 7.9–9.5 >9.5
Univariate (n = 6087) 1.13 (0.92–1.40) 1.0 1.17 (1.05–1.32)
Model 1 (n = 6074) 1.32 (1.05–1.66) 1.0 1.18 (1.05–1.34)
Model 2 (n = 5811) 1.40 (1.11–1.78) 1.0 1.23 (1.07–1.40)
Model 3 (n = 5590) 1.13 (0.87–1.46) 1.0 1.32 (1.14–1.52)
Serum PTH (pg/mL) <168 168–674 >674
Univariate (n = 6221) 1.63 (1.47–1.80) 1.0 1.16 (0.97–1.37)
Model 1 (n = 6209) 1.46 (1.31–1.64) 1.0 1.30 (1.08–1.58)
Model 2 (n = 5951) 1.35 (1.20–1.53) 1.0 1.48 (1.22–1.81)
Model 3 (n = 5590) 1.17 (1.02–1.33) 1.0 1.39 (1.13–1.72)
Intermediate category (used as reference—HR = 1.0) was the serum range of each parameter with a hazard ratio≤1.10 (<10% increase in the relative risk of mortality) in Figure 1. Each serum























increment) compared with others [2, 3, 8–10, 12, 13, 17, 21, 22,
26–29, 31]. However, despite several approaches (baseline or
time-dependent values), different outcomes (all-cause and
cardiovascular mortality) and the use of different strategies,
Tentori et al. obtained results similar to this study with the
lowest risk of mortality with serum phosphorus 3.6–5.0 mg/dL,
calcium 8.6–10.0 mg/dL and PTH 101–600 pg/mL.
One of the most attractive and practical contributions of this
new data from COSMOS is related to the strategy used to ﬁnd
the lowest mortality risk ranges for serum phosphorus, calcium
and PTH, which differs from the previous studies. In fact,
instead of using arbitrary categories, we determined as cut-off
value a predeﬁned percentage of HR increase (10%), which re-
presents quite a reasonable strategy that allows the use as a ref-
erence the lowest mortality risk values of the COSMOS
population. Furthermore, these ﬁgures were the base to obtain
what we called ‘the optimal or the safest serum ranges’ of the
CKD-MBD parameters in CKD5D patients. We decided to
ﬁx the limit of our range in a 10% increase of HR, but this strat-
egy offers the possibility of changing the percentage of increase
in HR allowing to wider or narrower the serum ranges in order
to relax or harden the recommended targets; in fact, even a 20%
F IGURE 3 : Serum calcium changes from baseline and relative risk of mortality. (A) Patients with baseline serum phosphorus between 7.9 and
9.5 mg/dL (patients with a HR < 1.1 in Figure 1B, number of observations: 15 254). (B) Patients with baseline serum calcium higher than 9.5 mg/dL.
Multivariate models were the same described in Figure 1 (number of observations: 6171). Serum calcium changes were considered as a time-varying
variable. The multivariate Model 3 included serum phosphorus and PTH (both as time-varying variables). Serum calcium changes from baseline
equal to 0 (no change) were used as reference (HR = 1.0) in both graphs.
F IGURE 2 : Serumphosphorus changes from baseline and relative risk ofmortality. (A) Patients with baseline serumphosphorus between 3.6 and
5.2 mg/dL (patients with <10% increase in the relative risk of mortality at baseline, HR < 1.1 in Figure 1A, number of observations: 9176). (B)
Patients with baseline serum phosphorus higher than 5.2 mg/dL (number of observations: 11 630). Multivariate models were the same described in
Figure 1. Serumphosphorus changes were considered as a time-varying variable. ThemultivariateModel 3 included serum calcium and PTH (both























increase is fully acceptable to deﬁne these safest ranges from an
epidemiological point of view.
Despite the safest serum ranges were obtained after adjust-
ment for treatments of CKD-MBD, to further study if these saf-
est ranges were applicable also to patients without therapeutic
intervention, as other authors did recently for serum PTH [45],
additional analyses were performed in a subcohort of patients
(n = 1771) not treated with VDRAs or calcimimetics at any
time during follow-up. The results obtained in this subcohort
suggest that the safest ranges used in this analyses for serum
phosphorus and PTH were valid (data not shown). However,
the analyses with patients not treated with any drug (PBAs,
VDRAs or calcimimetics) did not allow any kind of compari-
sons due to the reduced number of patients (n = 213).
So far, as Figure 5 shows, the serum ranges recommended by
the two widely used guidelines (K/DOQI and KDIGO) showed
important differences between them with the consequent im-
portant impact on the management of CKD patients. The COS-
MOS results are not recommendations, but they can be used as a
practical test to know if the current guideline targets are in agree-
ment with real new data of outcomes in CKD patients. The
serum phosphorus values associated with a lower risk of
F IGURE 4 : Serum PTH changes from baseline and relative risk of mortality. (A) Patients with baseline serum PTH between 168 and 674 pg/mL
(patients with a HR < 1.1 in Figure 1C, number of observations: 11 070). (B) Patients with baseline serum PTH lower than 168 pg/mL.Multivariate
models were the same described in Figure 1 (number of observations: 9271). Serum PTH changes from baseline were considered as a time-varying
variable. The multivariate Model 3 included serum phosphorus and calcium (both as time-varying variables). Serum PTH changes from baseline
equal to 0 (no change) were used as reference (HR = 1.0) in both graphs.
F IGURE 5 : Comparison of KDOQI and KDIGO recommended targets and COSMOS lowest mortality ranges. Grey arrows show the serum























mortality found in COSMOSwere similar and closer to K/DOQI
but higher than KDIGO recommendations (Figure 5). With re-
spect to calcium, the upper limit of the lowest mortality range
found in COSMOS was exactly the same as the K/DOQI recom-
mendation despite albumin-corrected values were used in the
latter; however, the lower limit was below the K/DOQI
recommendation (7.9 mg/dL in COSMOS and 8.4 mg/dL in K/
DOQI, Figure 5). Finally, regarding serum PTH, COSMOS re-
sults, in agreement with the KDIGO recommended values,
showed a wide and similar range in serum PTH values in
which there was no increase in the relative risk of mortality.
To better interpret the differences between the K/DOQI and
KDIGO PTH recommendations, it is necessary to remember
the approaches used by the two guidelines to obtain their
serum PTH targets. In KDOQI, the recommended serum
PTH values were based on bone turnover criteria with bone bi-
opsies as gold standard [46], meanwhile the KDIGO recom-
mendations were based on the relative risk of mortality
associated with serum PTH levels, the latter has also been the
approach used in COSMOS.
The present study also analysed the association between
improvement of the CKD-MBD parameters and mortality.
This is a ﬁeld where solid information is urgently needed.
However, due to ethical reasons, it is unlikely that randomized
long-term large scale clinical trials will be performed despite
the lack of information on survival beneﬁts with the control
of these parameters. In COSMOS, the 3-year follow-up di-
vided into six periods of 6 months, allowed a great number
of observations every 6 months (n = 28 167), a fact that may
partly mimic the follow-up of a clinical trial and gives the
possibility to evaluate if there are beneﬁts in outcomes in pa-
tients moving from the dangerous to the recommended
ranges.
The three most frequent risk groups of patients that were
speciﬁcally analysed in the present study; patients with high
serum phosphorus (>5.2 mg/dL, mean 6.5 mg/dL) or serum
calcium (>9.5 mg/dL, mean 10.0 mg/dL) at baseline (Figure 2B
and 3B) showed that decreases in serum phosphorus and cal-
cium towards the ‘safest ranges’ were associated with a lower
relative risk of mortality. Similarly, patients with low baseline
serum PTH levels (<168 pg/mL, mean 88.8 pg/mL) showed
that increases in serum PTH were associated with a lower risk
of mortality. These are very promising results which reinforce
the fact that the better control of the CKD-MBD biochemical
parameters may positively impact on survival. The association
of serum changes in patients below the safest ranges for serum
phosphorus and calcium and above the safest range for serum
PTH was not assessed because the reduced number of patients
did not allow the analysis.
In the three groups of patients at higher risk in whom the
analysis was performed, the reduction of the relative risk
of mortality was 12% for phosphorus and 8% for calcium
(Figures 2B and 3B) while it was 31% for an increase of
200 pg/mL in serum PTH (Figure 4B).
The impact of changes in serum CKD-MBD biochemical
parameters and outcomes has been already addressed by
other investigators but in shorter periods. One study with a
follow-up of between 6 and 18 months [8] and categorization
of serum phosphorus and calcium changes from baseline in-
tervals of 0.5 mg/dL for phosphorus and 0.2 mg/dL for cal-
cium, found that in patients within K/DOQI ranges both,
increases or decreases in serum phosphorus and calcium
were associated with an increased risk of mortality. Another
study [29] in incident haemodialysis and peritoneal dialysis
patients, found that patients with low levels of serum phos-
phorus at baseline that remained low after 6 months showed
a better survival than those with high serum phosphorus levels
at baseline that subsequently decreased in the following 6
months. At ﬁrst sight, the previous results may appear in dis-
agreement with the present study; however, in COSMOS, the
reference (HR = 1.0) was patients with no changes in serum
phosphorus during follow-up (Figure 2B) which renders the
comparisons difﬁcult.
A limitation of the study is its observational nature, which
does not allow to make causal statements. In addition, as it
has been explained, in some groups of patients there was not
enough number of patients to investigate if increments in
patients with serum values of serum phosphorus and calcium
<3.6 and 7.9 mg/dL, respectively, or reductions serum PTH
from values >674 pg/mL were associated with changes in the
relative risk of mortality. In addition, the low number of pa-
tients not receiving any kind of drugs to control CKD-MBD
serum parameters did not allow to investigate separately
if spontaneous changes in serum parameters (not related to
medical intervention) were associated with an improved risk
of mortality. Besides limitations, COSMOS also has great
strengths, which mainly relies on its careful design explained
in brief in the methods section of this paper but in detail in pre-
vious papers [15, 16]. COSMOS used random selection of cen-
tres and patients with a proportional sampling according to the
haemodialysis patients of each country.
In summary, in COSMOS, a non-linear relationship be-
tween serum CKD-MBD biochemical parameters and mortal-
ity risk was found. Low and high serum levels of serum
phosphorus, calcium and PTH were associated with a higher
relative risk of mortality. New mortality risk ranges were de-
scribed: 3.6–5.2 mg/dL for serum phosphorus, 7.9–9.5 mg/
dL for serum calcium and 168–674 pg/mL for serum PTH.
In addition, in the three groups of patients with a higher
risk of mortality (serum phosphorus >5.2 mg/dL, serum cal-
cium >9.5 mg/dL and serum PTH <168 pg/mL), decreases
in serum phosphorus and calcium and increases in serum
PTH during the follow-up were associated with a signiﬁcant
lower risk of mortality. The latter, together with new serum
targets described, makes this COSMOS analysis a relevant
contribution to better know the impact of the control of
serum CKD-MBD parameters on survival. In addition, this
new information can be of help for the preparation of future
CKD-MBD guidelines.
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